ERBB2 and gastric cancer: Trastuzumab and pertuzumab have significantly improved the outlook for HER2-positive breast and gastric cancer patients.38,39 Recently, the trastuzumab-based antibody drug conjugate T-DM1 was approved in metastatic breast cancer, representing another significant milestone in targeting HER2.